Table 2.
Characteristics of the procedures and in-hospital antithrombotic therapy
| Variables | Overall (n = 588) | Femoral (n = 410) | Radial (n = 178) | p |
|---|---|---|---|---|
| Procedural success rate, n (%) | 568 (96.6) | 397 (96.8) | 171 (96.1) | 0.627 |
| Stent implantation, n (%) | 562 (98.9) | 395 (99.5) | 167 (97.7) | 0.192 |
| Drug-eluting stent, n (%) | 126 (21.4) | 116 (28.3) | 10 (5.6) | < 0.001 |
| Non-drug-eluting stent, n (%) | 436 (74.1) | 279 (68.0) | 157 (88.2) | < 0.001 |
| One-vessel, n (%) | 275 (48.5) | 197 (49.1) | 78 (47.0) | 0.369 |
| Two-vessel, n (%) | 172 (30.3) | 131 (32.7) | 41 (24.7) | 0.030 |
| Multivessel, n (%) | 111 (19.6) | 69 (17.2) | 42 (25.3) | 0.066 |
| Acetylsalicylic acid, n (%) | 578 (98.3) | 405 (98.8) | 173 (97.2) | 0.179 |
| Clopidogrel, n (%) | 561 (95.4) | 395 (96.3) | 166 (93.3) | 0.131 |
| Prasugrel, n (%) | 4 (0.7) | 4 (100.0) | 0 (0.0) | 0.320 |
| Ticagrelor, n (%) | 7 (1.2) | 1 (0.2) | 6 (3.4) | 0.004 |
| Glycoprotein IIb-IIIa inhibitors, n (%) | 105 (17.9) | 61 (14.9) | 44 (24.7) | 0.005 |
| Unfractioned heparin, n (%) | 101 (17.2) | 83 (20.2) | 18 (10.1) | 0.003 |
| Enoxaparin, n (%) | 377 (64.1) | 261 (63.7) | 116 (65.2) | 0.779 |
| Fondaparinux, n (%) | 31 (5.3) | 6 (1.5) | 25 (14.0) | < 0.001 |